Literature DB >> 7326748

The 2.2 kb E1b mRNA of human Ad12 and Ad5 codes for two tumor antigens starting at different AUG triplets.

J L Bos, L J Polder, R Bernards, P I Schrier, P J van den Elsen, A J van der Eb, H van Ormondt.   

Abstract

By nucleotide sequence analysis and S1 nuclease mapping we have determined the structural organization of early region E1b of Ad12. We have also revised the nucleotide sequence of the E1b region of Ad5. Both regions have an identical structural organization and show considerable homology at the nucleotide level. The major tumor antigens (Ad12, 19 and 54 kilodaltons [kd]); Ad5, 21 and 55 kd) are encoded in two overlapping reading frames. A single mRNA of 2.2 kilobases codes for both these proteins, depending on which AUG triplet serves as the start codon: the 19-21 kd protein initiates at the 5'-promximal AUG; the 54-55 kd protein initiates at the second AUG in another reading frame. Peptide mapping shows that the small and large tumor antigens do not share common tryptic peptides, in accordance with the nucleic acid sequence data. In addition, the 19-21 kd protein can also by synthesized from a one kilobase mRNA. Finally, the gene for the Ad12 analog of protein IX is characterized.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7326748     DOI: 10.1016/0092-8674(81)90366-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  113 in total

1.  The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid.

Authors:  A Akalu; H Liebermann; U Bauer; H Granzow; W Seidel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Overexpression of the E1B 55-kilodalton (482R) protein of human adenovirus type 12 appears to permit efficient transformation of primary baby rat kidney cells in the absence of the E1B 19-kilodalton protein.

Authors:  S Zhang; S Mak; P E Branton
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease.

Authors:  M F Kagnoff; Y J Paterson; P J Kumar; D D Kasarda; F R Carbone; D J Unsworth; R K Austin
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

Review 4.  Expression and interactions of human adenovirus oncoproteins.

Authors:  P A Boulanger; G E Blair
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

5.  Genomic characterization of human adenovirus type 4 strains isolated worldwide since 1953 identifies two separable phylogroups evolving at different rates from their most recent common ancestor.

Authors:  Gabriel Gonzalez; Camden R Bair; Daryl M Lamson; Hidemi Watanabe; Laura Panto; Michael J Carr; Adriana E Kajon
Journal:  Virology       Date:  2019-09-08       Impact factor: 3.616

6.  Activation of RNA polymerase III transcription of human Alu repetitive elements by adenovirus type 5: requirement for the E1b 58-kilodalton protein and the products of E4 open reading frames 3 and 6.

Authors:  B Panning; J R Smiley
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  The use of monoclonal antibodies to study the proteins specified by the transforming region of human adenoviruses.

Authors:  M E Blair Zajdel; M D Barker; S C Dixon; G E Blair
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

8.  Transfection with extracellularly UV-damaged DNA induces human and rat cells to express a mutator phenotype towards parvovirus H-1.

Authors:  C Dinsart; J J Cornelis; B Klein; A J van der Eb; J Rommelaere
Journal:  Mol Cell Biol       Date:  1984-02       Impact factor: 4.272

9.  Oncogenicity by adenovirus is not determined by the transforming region only.

Authors:  R Bernards; M G de Leeuw; M J Vaessen; A Houweling; A J van der Eb
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Early region 1B of adenovirus 2 encodes two coterminal proteins of 495 and 155 amino acid residues.

Authors:  C W Anderson; R C Schmitt; J E Smart; J B Lewis
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.